Polyclonal and monoclonal antibodies in renal transplant

Abstract

Transplantation is the standard of care for end-stage renal disease patients, but we still have a long way to go, as we need to improve long-term outcomes. The manipulation of the immune system is a delicate undertaking, with risks of adverse events; therefore, risk versus benefit needs to be carefully evaluated and treatment needs to be individualized.

Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants

“…In addition, a variety of new agents, such as borezomib or eculizumab, have shown promise in reducing DSAs and overcoming AMR. 18,19 Whether they may be beneficial to desensitization is unclear. Ilahe et al 19 provided a thought-provoking overview on some of the benefits and drawbacks of these new agents and their potential application to desensitization efforts.…”